Search
for
Sort by
Research 91–120 of 108
- A comment on the post-finasteride syndrome
- Clinical Management of Prostate Cancer in High-Risk Genetic Mutation Carriers
- Ent-kaurane-type diterpenoids from Isodonis Herba activate human hair follicle dermal papilla cells proliferation via the Akt/GSK-3β/β-catenin transduction pathway
- Risk of Depression after 5 Alpha Reductase Inhibitor Medication: Meta-Analysis
- IsoPSA Performance Characteristics are Unaffected by 5-Alpha Reductase Inhibitors or Alpha-Blockers: Results From the IsoPSA Validation Study
- Primärprävention urologischer Tumore: Prostatakarzinom
- Oral Presentations: Abstracts of the Urological Society of Australia and New Zealand Annual Scientific Meeting, 25–28 February 2023, Melbourne, Australia
- Logic-based modeling and drug repurposing for the prediction of novel therapeutic targets and combination regimens against E2F1-driven melanoma progression
- 5-Alpha Reductase Inhibitor Use and Prostate Cancer Prevention: A Victim of the Times?
- Trailing the Path to Preventive Oncology
- ENZYMES
- Synopsis: 2005 Annual Meeting of the American Society of Andrology
- 5-alpha reductase inhibitors use in prostatic disease and beyond
- Provenge is Talk of GU Malignancies Congress
- Pharmacogenetics of the Androgen Metabolic Pathway
- Dihydrotestosterone and 5α-Reductase
- Prostate cancer and androgenic alopecia: The role of finasteride as a dual agent
- Post-Finasteride Syndrome (PFS) Update: Point/Counterpoint
- PCPT, MTOPS and the use of 5ARIs: a Canadian consensus regarding implications for clinical practice
- PCPT Results Could Affect Trial on Testosterone Replacement
- Étude PCPT : les biais attendus et leur gestion
- L’étude PCPT
- L'etude PCPT : regards d'un urologue intéressé
- 5α-Reductase Inhibitors and Chemoprevention: The PCPT and Beyond
- Pertinence d’une chimioprévention à partir de l’étude PCPT
- Level-1 Data From the REDUCE Study and the PCPT Data
- Le point de vue du pathologiste concernant l’étude PCPT
- 5-α-Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review
- Alcohol and Prostate Cancer: Time to Draw Conclusions
- Three Considerations Before Advising 5-α-Reductase Inhibitors for Chemoprevention